Covid FLiRT has spread to 14 countries. How is CureVac responding?

As of 2024, CureVac's COVID-19 vaccine is undergoing clinical trials. Currently, the second-generation mRNA COVID-19 vaccine developed in collaboration with GSK is in Phase II trials.

Progress and Trial Data
In the Phase II clinical trials, CureVac's monovalent vaccine CV0601 and bivalent vaccine CV0701 both showed positive results. The monovalent vaccine, targeting the Omicron BA.4-5 variant, demonstrated a fivefold increase in neutralizing antibody titers 29 days post-vaccination, compared to a 3.6-fold increase with the comparator vaccine. The bivalent vaccine, targeting both the Omicron BA.4-5 variant and the original SARS-CoV-2 virus, also showed higher neutralizing antibody titers at various doses compared to the comparator vaccine.

Safety and Immunogenicity
The trials indicated that all dose groups of the vaccine candidates were well-tolerated and safe, and they performed excellently in generating neutralizing antibodies. These trials were conducted in Australia with 427 healthy adult participants.

Market Launch Plans
CureVac is currently discussing the pathway for Phase III clinical trials and market release plans with regulatory authorities. Following the completion of Phase III trials, the vaccine is scheduled for market release.

Future Outlook
The collaboration between CureVac and GSK aims to address potential future COVID-19 variants and other pandemics, ensuring effective protection for the most vulnerable groups, such as the elderly and those with compromised immune systems.